Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSIs) in the UK are common and associated with significant morbidity and mortality. Vancomycin is the usual first-line therapy. However, vancomycin treatment of BSIs due to MRSA strains with vancomycin MICs of 1 -2 mg/L is successful in ,10% of cases. No consensus exists on when to use newer agents, particularly when vancomycin MICs are .1 mg/L. We therefore surveyed UK practices of the management of MRSA BSIs due to isolates with increased vancomycin MICs.
Introduction
In the UK, there is a mandatory reporting scheme in place for all methicillin-resistant Staphylococcus aureus (MRSA) isolates from bacteraemic patients. MRSA bacteraemias are associated with significant morbidity and mortality, and are proving an increasing burden in healthcare-associated infections. Studies have demonstrated the poorer performance of vancomycin compared with the newer agents in vitro, 1 and in patients suffering from methicillin-susceptible S. aureus as well as MRSA bacteraemias. 2 -4 Whilst newer agents targeted against Gram-positive bacteria are available, there is little consensus as to when these agents should be used. Whilst the BSAC has maintained the breakpoint for MRSA of vancomycin as 4 mg/L, the CLSI has lowered the breakpoint to 2 mg/L. Even this level has been brought into question, as studies indicate that MRSA infections due to strains with vancomycin MICs of 1 -2 mg/L were treated successfully in ,10% of cases. 5 Recently published guidelines have recommended the use of vancomycin in the management of severe MRSA infection. 6 We therefore also attempted to ascertain national practices of management of MRSA isolates with increased MICs of vancomycin.
The pharmacodynamics of vancomycin also appears to play a role in clinical outcomes and these can be determined by the serum vancomycin values. Moise-Broder et al. 7 suggested that the steady-state 24 h area under the concentration-time curve (AUC 24 ) divided by the MIC (AUC 24 /MIC) values of vancomycin should aim to be .400, in order that a favourable therapeutic outcome is achieved. We were also keen to see which serum levels of vancomycin UK laboratories were reporting as therapeutic.
It is widely accepted 8 that the management of MRSA bacteraemias is multidisciplinary, involving clinicians, medical microbiologists, infection control teams and nursing staff. We wanted to establish who follows up these patients and who is involved in local root-cause analyses (RCAs).
Methods
Consultant microbiologists in the UK were contacted by e-mail. The e-mail contained the link to an online survey hosted at www .surveymonkey.com. Respondents were asked to answer the questions as individuals and not as laboratories, as differences in intralaboratory prescribing were a key part of this study. The survey questions are available as Supplementary data at JAC online (http://jac.oxfordjournals.org/).
Data were collated by www.surveymonkey.com, and responses were downloaded both as summaries and detailed Excel spreadsheets. The data were analysed by the authors using Microsoft w Excel 2007.
Results
There are 744 members of the Royal College of Pathologists (RCP) who have indicated a specialty of medical microbiology (information supplied by the RCP membership department). Five hundred and seventy-one e-mails were sent out. There were a total of 108 respondents for the survey, of whom 47 (43.5%) completed the survey. We found that 42% of respondents would use vancomycin alone for non-complicated infections, whilst for cardiac or orthopaedic infections, 49% would add rifampicin. Very few respondents would use daptomycin, linezolid or tigecycline. Vancomycin singly or in combination appears to be the mainstay of treatment, which appears to be consistent even in light of evidence of reduced susceptibility or clinical failure. Newer agents are used in exceptional cases, but the use of these agents is within their licence.
We found that the majority of the respondents (69.4%) would use linezolid as a second-line agent, with only 19.1% considering the use of daptomycin. As the vancomycin MIC approaches 4 mg/L (Table 1) , respondents would use daptomycin (81%) or linezolid (91%), irrespective of the patients' clinical response.
The average number of days for which antibiotic treatment for an MRSA bacteraemia secondary to a non-removable source would be given was 29.2 days. Ninety-four percent of respondents stated that the use of daptomycin, linezolid and tigecycline was subject to approval by microbiology.
Some 85.4% of respondents stated that all MRSA bacteraemia cases were reviewed by a medical microbiologist, although we did not specify the nature or frequency of that review. The majority (86.3%) of the respondents stated that infectious disease physicians or infection control nurses were not involved in the review process.
Discussion
This study has highlighted a wide variation in the laboratory processing of MRSA isolated from blood cultures. The measurement of vancomycin MICs is not currently routine practice for all MRSA bacteraemia isolates and, based upon the close relationship between susceptibility and pharmacodynamics, we feel that it should be. There is a wide variation in the detection and management of MRSA bacteraemias in the UK, partially as a result of the lack of published guidelines, as well as discrepancies in MIC reporting based on the methodology used. 9 As Prakash et al. state, 9 the fact that a single dilution difference in the vancomycin MIC in the range of 0.5-2 mg/L has clinical implications should require management guidelines to clearly state the method of measurement. RCAs are a recommended methodology for the investigation of causality, as directed by the Department of Health. RCAs can be used for the education of clinical staff and the development of steps towards prevention. A standardized pro forma is available, and these investigations are usually attended, if not led, by the medical microbiologist and not the infectious disease physician. 10 This study, of course, is not without its flaws. Even though it was anonymous, respondents may have felt compelled to report their prescribing within the licence, which may not be accurate. Surveys of this sort are subject to selection bias, which cannot be controlled for by altering the survey design. Survey length and complexity are key issues when completing an online survey. Complexity has a profound effect on response rates. The design of response alternatives (open and closed questions, frequency scales, reference periods, and rating scales) and question context (researcher's epistemic interest and adjacent questions) can create bias that may destroy the quality of any survey.
In conclusion, the online survey appears to be a useful tool in gauging clinical practices. The practices in the UK are in line with national guidelines. There is a need for more randomized controlled trials to demonstrate the efficacy of newer agents in the management of MRSA bacteraemias.
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